Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Cooper

Showing results (221-230 of 399) with videos related to

Pageof 40
Sort By:
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 12, 2015
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 DiabetesMark E Cooper, Vlado Perkovic, Janet B McGill, et al.
Diabetologia|May 12, 2016
The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosisBryna S M Chow, Christine Koulis, Pooja Krishnaswamy, et al.
Clinical Science (London, England : 1979)|September 30, 2015
miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7Aaron D McClelland, Michal Herman-Edelstein, Radko Komers, et al.
The American Journal of Pathology|January 1, 2003
The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studiesChristina J Moravski, Sandford L Skinner, Anthony J Stubbs, et al.
Clinical Science (London, England : 1979)|January 20, 2022
Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney diseaseJakob A Østergaard, Jay C Jha, Arpeeta Sharma, et al.
Journal of Hypertension|December 13, 2018
Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuriaMark E Cooper, Vlado Perkovic, Per-Henrik Groop, et al.
Diabetes|September 21, 2010
Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I functionAntonia G Miller, Genevieve Tan, Katrina J Binger, et al.
Journal of the American Society of Nephrology : JASN|August 19, 2005
Interactions between renin angiotensin system and advanced glycation in the kidneyMerlin C Thomas, Christos Tikellis, Wendy M Burns, et al.
Journal of the American Society of Nephrology : JASN|August 18, 2006
Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal diseaseWendy C Burns, Stephen M Twigg, Josephine M Forbes, et al.
Diabetologia|June 19, 2016
The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetesDavid Cherney, Søren S Lund, Bruce A Perkins, et al.
Pageof 40

Showing results (221-230 of 399) with videos related to

Sort By:
Pageof 40
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 12, 2015
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 DiabetesMark E Cooper, Vlado Perkovic, Janet B McGill, et al.
Diabetologia|May 12, 2016
The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosisBryna S M Chow, Christine Koulis, Pooja Krishnaswamy, et al.
Clinical Science (London, England : 1979)|September 30, 2015
miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7Aaron D McClelland, Michal Herman-Edelstein, Radko Komers, et al.
The American Journal of Pathology|January 1, 2003
The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studiesChristina J Moravski, Sandford L Skinner, Anthony J Stubbs, et al.
Clinical Science (London, England : 1979)|January 20, 2022
Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney diseaseJakob A Østergaard, Jay C Jha, Arpeeta Sharma, et al.
Journal of Hypertension|December 13, 2018
Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuriaMark E Cooper, Vlado Perkovic, Per-Henrik Groop, et al.
Diabetes|September 21, 2010
Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I functionAntonia G Miller, Genevieve Tan, Katrina J Binger, et al.
Journal of the American Society of Nephrology : JASN|August 19, 2005
Interactions between renin angiotensin system and advanced glycation in the kidneyMerlin C Thomas, Christos Tikellis, Wendy M Burns, et al.
Journal of the American Society of Nephrology : JASN|August 18, 2006
Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal diseaseWendy C Burns, Stephen M Twigg, Josephine M Forbes, et al.
Diabetologia|June 19, 2016
The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetesDavid Cherney, Søren S Lund, Bruce A Perkins, et al.
Pageof 40